|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.525 AUD | -1.87% |
|
-0.94% | -21.05% |
| Apr. 19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
| Apr. 15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
INOVIQ Ltd reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was AUD 8.97 million compared to AUD 18.2 million a year ago. Basic loss per share from continuing operations was AUD 0.0975 compared to AUD 0.2003 a year ago.
Diluted loss per share from continuing operations was AUD 0.0975 compared to AUD 0.2003 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.05% | 31.51M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
INOVIQ LTD 
